https://www.jnj.com/rss-feed/all.rss RSS feed all en-US Thu, 23 Jul 2026 12:44:29 GMT https://www.jnj.com/media-center/press-releases/tecvayli-talvey-reduced-the-risk-of-disease-progression-or-death-by-89-and-the-risk-of-death-by-62-in-earlier-line-relapsed-refractory-multiple-myeloma · Investigational MonumenTAL-6 trial is the first and only Phase 3 study of a dual antigen, BCMA and GPRC5D targeting regimen in relapsed/refractory multiple myeloma · Fifth positive Phase 3 study evaluating Johnson & Johnson's multiple myeloma T-cell therapy portfolio in second line, further strengthening the company's leadership and commitment to advancing immunotherapy-based regimens earlier in the treatment journey Thu, 23 Jul 2026 12:44:29 GMT https://www.jnj.com/media-center/press-releases/tecvayli-talvey-reduced-the-risk-of-disease-progression-or-death-by-89-and-the-risk-of-death-by-62-in-earlier-line-relapsed-refractory-multiple-myeloma https://www.jnj.com/media-center/press-releases/johnson-johnson-receives-fda-market-authorization-in-the-u-s-for-its-ottava-robotic-surgical-system Wed, 22 Jul 2026 11:01:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-receives-fda-market-authorization-in-the-u-s-for-its-ottava-robotic-surgical-system https://www.jnj.com/media-center/press-releases/depuy-synthes-acquires-expanding-innovations Transaction will bring expandable interbody cage solutions to DePuy Synthes' Spine portfolio to strengthen position across the lumbar fusion market Thu, 16 Jul 2026 12:00:00 GMT https://www.jnj.com/media-center/press-releases/depuy-synthes-acquires-expanding-innovations https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-collaboration-with-time-to-introduce-new-healthcare-champion-of-the-year-award • New branded recognition will spotlight the care, innovation and grit of U.S. healthcare professionals making a meaningful difference for patients, colleagues and communities. • The collaboration will recognize healthcare leaders helping strengthen care amid growing pressure on health systems. • Nominations will open on July 16, 2026 and close at 5:00 p.m. ET on August 28, 2026. Thu, 16 Jul 2026 12:00:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-collaboration-with-time-to-introduce-new-healthcare-champion-of-the-year-award https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-quarterly-dividend-for-third-quarter-2026 Wed, 15 Jul 2026 10:25:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-quarterly-dividend-for-third-quarter-2026 https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q2-2026-results-raises-2026-outlook 2025 Second-Quarter reported sales growth of 5.8% to $23.7 Billion with operational growth of 4.6%* and adjusted operational growth of 3.0%* • Wed, 15 Jul 2026 10:20:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q2-2026-results-raises-2026-outlook https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-FDA-approval-for-the-Dual-Energy-Thermocool-Smarttouch-SF-platform · Dual Energy THERMOCOOL SMARTTOUCH SF Platform brings pulse field and radiofrequency energy together in a single catheter. · Integrated with the CARTO ecosystem, the platform gives physicians greater versatility to tailor treatment based on patient anatomy and case complexity.i Wed, 08 Jul 2026 11:45:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-FDA-approval-for-the-Dual-Energy-Thermocool-Smarttouch-SF-platform https://www.jnj.com/media-center/press-releases/depuy-synthes-appoints-christina-zamarro-as-chief-financial-officer Mon, 29 Jun 2026 20:30:00 GMT https://www.jnj.com/media-center/press-releases/depuy-synthes-appoints-christina-zamarro-as-chief-financial-officer https://www.jnj.com/media-center/press-releases/johnson-johnson-presents-new-imaavy-nipocalimab-aahu-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalized-myasthenia-gravis · New analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+a, anti-MuSK+b adult patients with generalized myasthenia gravis (gMG) including those early in their disease, participants with lower symptom burden and those who experienced common infections · To address an important evidence gap, the PETUNIAc study design will be presented – demonstrating the innovative way pregnancy outcomes data will be collected following treatment with IMAAVY · IMAAVY, an immunoselective neonatal Fc receptor (FcRn) blocker, is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with generalized myasthenia gravis (gMG) Fri, 26 Jun 2026 16:45:17 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-presents-new-imaavy-nipocalimab-aahu-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalized-myasthenia-gravis https://www.jnj.com/media-center/press-releases/chmp-recommendation-advances-johnson-johnsons-tecvayli-teclistamab-plus-daratumumab-as-a-potential-standard-of-care-for-relapsed-refractory-multiple-myeloma Recommendation supported by unprecedented Phase 3 data, demonstrating that TECVAYLI® in combination with daratumumab achieved statistically significant improvements in progression-free and overall survival versus standard of care1 Pending approval, this novel complementary immunotherapy combination is positioned to delay disease progression for patients treated as early as second line, with 83% of patients alive at three years1 Fri, 26 Jun 2026 12:11:23 GMT https://www.jnj.com/media-center/press-releases/chmp-recommendation-advances-johnson-johnsons-tecvayli-teclistamab-plus-daratumumab-as-a-potential-standard-of-care-for-relapsed-refractory-multiple-myeloma https://www.jnj.com/media-center/press-releases/johnson-johnson-begins-enrollment-in-pivotal-studies-evaluating-first-of-its-kind-carotid-ivl-platform · U.S. IDE study program will evaluate the purpose-built Shockwave™ SkyRunner Carotid IVL System designed to address the challenges of calcification in carotid arteries prior to stenting · Clinical program is part of Johnson & Johnson’s plan to enhance treatment options for patients with carotid artery disease, which accounts for up to one-third of all strokes Thu, 25 Jun 2026 11:45:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-begins-enrollment-in-pivotal-studies-evaluating-first-of-its-kind-carotid-ivl-platform https://www.jnj.com/media-center/press-releases/johnson-johnson-advances-cardiac-ablation-technology-in-europe-with-availability-of-dual-energy-thermocool-smarttouch-sf-platform The Dual Energy THERMOCOOL SMARTTOUCH SF Platform combines pulsed field and radiofrequency energy delivery in a unified and integrated treatment platformi Thu, 25 Jun 2026 09:00:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-advances-cardiac-ablation-technology-in-europe-with-availability-of-dual-energy-thermocool-smarttouch-sf-platform https://www.jnj.com/media-center/press-releases/johnson-johnson-highlights-positive-results-from-membrane-trial-published-in-jama-neurology •Study demonstrated middle meningeal artery embolization with TRUFILL n-BCA was associated with reduced chronic subdural hematoma recurrence or progression versus standard of care alone •Findings support the growing role of MMA embolization in chronic subdural hematoma care Fri, 19 Jun 2026 11:57:10 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-highlights-positive-results-from-membrane-trial-published-in-jama-neurology https://www.jnj.com/media-center/press-releases/johnson-johnson-invests-more-than-1-billion-to-strengthen-u-s-vision-manufacturing-in-jacksonville-florida Investment includes new advanced manufacturing and packaging technologies and a new state-of-the-art distribution facility to scale the Company’s U.S. Vision operations, enhance supply chain resilience, and meet the needs of more than 40 million patients Investment is part of the Company’s ongoing $55 billion commitment to U.S. manufacturing, research and development, and technology through early 2029 Building on more than 40 years of leadership in Florida, the investment supports 3,500 Jacksonville employees and strengthens Johnson & Johnson’s $6 billion annual economic impact across the state Mon, 15 Jun 2026 10:02:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-invests-more-than-1-billion-to-strengthen-u-s-vision-manufacturing-in-jacksonville-florida https://www.jnj.com/media-center/press-releases/new-talvey-talquetamab-tgvs-plus-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-data-demonstrate-the-strength-of-a-bispecific-combination-in-earlier-line-relapsed-or-refractory-multiple-myeloma Sat, 13 Jun 2026 11:41:27 GMT https://www.jnj.com/media-center/press-releases/new-talvey-talquetamab-tgvs-plus-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-data-demonstrate-the-strength-of-a-bispecific-combination-in-earlier-line-relapsed-or-refractory-multiple-myeloma https://www.jnj.com/media-center/press-releases/johnson-johnson-expands-u-s-availability-of-tecnis-puresee-iol-an-advanced-lens-option-for-cataract-surgeons-and-patients • Expanded U.S. availability paired with new patient lifestyle quiz encourages informed decision-making ahead of cataract surgery. • Cataracts are one of the leading causes of vision impairment.1 Nearly 20% of Americans aged 40+ live with cataracts that make everyday tasks more challenging, yet only 5% have had cataract surgery.2 • Over half a million eyes worldwide have already experienced clearer, extended range of vision with TECNIS PureSee IOL after cataract surgery.3,4 • 97% of patients would recommend TECNIS PureSee IOL to friends or family.5 Thu, 11 Jun 2026 12:22:39 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-expands-u-s-availability-of-tecnis-puresee-iol-an-advanced-lens-option-for-cataract-surgeons-and-patients https://www.jnj.com/media-center/press-releases/imaavy-nipocalimab-aahu-demonstrates-durable-hemoglobin-response-and-rapid-onset-of-effect-in-pivotal-phase-2-3-study-in-warm-autoimmune-hemolytic-anemia-waiha-an-autoantibody-driven-disease-with-no-fda-approved-therapies · Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglobin responseb, with mean hemoglobin improvement of at least 1 g/dL as early as Week 1c · More patients treated with IMAAVY experienced improvement in fatigued and corticosteroid dose reductionse · IMAAVY is designed to target pathogenic immunoglobulin G (IgG) autoantibodies in warm autoimmune hemolytic anemia while preserving immune function · Pivotal results will be presented at EHA 2026 Thu, 11 Jun 2026 11:36:49 GMT https://www.jnj.com/media-center/press-releases/imaavy-nipocalimab-aahu-demonstrates-durable-hemoglobin-response-and-rapid-onset-of-effect-in-pivotal-phase-2-3-study-in-warm-autoimmune-hemolytic-anemia-waiha-an-autoantibody-driven-disease-with-no-fda-approved-therapies https://www.jnj.com/media-center/press-releases/depuy-synthes-launches-velys-hip-navigation-with-ai-to-support-intraoperative-consistency-and-efficiency-in-total-hip-arthroplasty Use of VELYS™ Hip Navigation with AI Assistance demonstrated reproducible landmark identification and reduced workflow time by 57% compared to manual workflows (5.33 vs. 2.27 minutes) 1 Tue, 09 Jun 2026 12:02:14 GMT https://www.jnj.com/media-center/press-releases/depuy-synthes-launches-velys-hip-navigation-with-ai-to-support-intraoperative-consistency-and-efficiency-in-total-hip-arthroplasty https://www.jnj.com/media-center/press-releases/johnson-johnson-to-acquire-firefly-bio-inc-to-expand-oncology-pipeline-with-novel-degrader-antibody-conjugate-platform • Expands the Company’s expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers • Acquisition adds a proprietary degrader antibody conjugate platform designed to overcome key limitations of existing therapeutic approaches • Strengthens leadership in next-generation antibody engineering to accelerate oncology innovation Mon, 08 Jun 2026 12:00:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-to-acquire-firefly-bio-inc-to-expand-oncology-pipeline-with-novel-degrader-antibody-conjugate-platform https://www.jnj.com/media-center/press-releases/johnson-johnson-late-breaking-results-show-nipocalimab-significantly-reduced-systemic-lupus-erythematosus-sle-disease-activity-in-a-phase-2-study · Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with this disease while preserving immune function · Results demonstrated significant reduction of systemic lupus erythematosus disease activity which continued beyond the 24-week primary endpoint, and were sustained through Week 52 in the nipocalimab 15 mg/kg groupa · The ongoing Phase 3 study of nipocalimab is currently recruiting people living with systemic lupus erythematosus – a debilitating autoantibody-driven disease which can lead to systemic organ damage Wed, 03 Jun 2026 12:00:18 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-late-breaking-results-show-nipocalimab-significantly-reduced-systemic-lupus-erythematosus-sle-disease-activity-in-a-phase-2-study https://www.jnj.com/media-center/press-releases/johnson-johnson-presents-new-data-further-reinforcing-the-role-of-nipocalimab-in-lowering-the-autoantibodies-driving-sjogrens-disease · Nipocalimab, an immunoselective neonatal Fc receptor (FcRn) blocker, is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with Sjögren’s disease while preserving immune function · New exploratory analysis of Phase 2 study data shows a strong correlation between autoantibody levels and even greater clinical response rates of participants in the nipocalimab treatment group · Previously reported data from the Phase 2 study showed nipocalimab reduced Sjögren’s disease activity and severity, with potential to address systemic manifestations and the most burdensome patient-reported symptoms including dryness, fatigue and pain · Nipocalimab is the only FcRn blocker granted both Breakthrough Therapy Designation and Fast Track Designation by the U.S. FDA for the treatment of adults with moderate-to-severe Sjögren’s disease. Wed, 03 Jun 2026 11:46:36 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-presents-new-data-further-reinforcing-the-role-of-nipocalimab-in-lowering-the-autoantibodies-driving-sjogrens-disease https://www.jnj.com/media-center/press-releases/johnson-johnson-phase-3-prostate-cancer-study-shows-erleada-apalutamide-before-and-after-surgery-significantly-reduces-risk-of-metastasis-or-death-breaking-a-decades-long-treatment-paradigm • Patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20% reduction in the risk of developing metastasis or death • Data selected to open the plenary presentation at ASCO 2026 and published in The New England Journal of Medicine Sun, 31 May 2026 12:00:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-phase-3-prostate-cancer-study-shows-erleada-apalutamide-before-and-after-surgery-significantly-reduces-risk-of-metastasis-or-death-breaking-a-decades-long-treatment-paradigm https://www.jnj.com/media-center/press-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-pivotal-data-show-strong-and-durable-responses-in-advanced-head-and-neck-cancer-where-options-remain-limited • More than one-third of responders with previously treated disease achieved complete responses, with median duration of response not yet reached, as reported in new Journal of Clinical Oncology publication • RYBREVANT FASPRO™, an EGFR- and MET-targeting dual inhibitor, is the first and only subcutaneous therapy being evaluated in this setting • Johnson & Johnson submitted a supplemental Biologics License Application to U.S. FDA seeking approval for this indication Sun, 31 May 2026 12:00:00 GMT https://www.jnj.com/media-center/press-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-pivotal-data-show-strong-and-durable-responses-in-advanced-head-and-neck-cancer-where-options-remain-limited https://www.jnj.com/media-center/press-releases/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-demonstrates-prolonged-clinical-benefit-as-a-first-line-treatment-for-atypical-egfr-mutated-non-small-cell-lung-cancer • Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson’s RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated disease • Consistent responses observed across atypical EGFR mutation subgroups, including those historically associated with poorer outcomes • ASCO 2026 results reinforce the significance of RYBREVANT®-based regimens for patients across EGFR mutations Fri, 29 May 2026 18:00:00 GMT https://www.jnj.com/media-center/press-releases/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-demonstrates-prolonged-clinical-benefit-as-a-first-line-treatment-for-atypical-egfr-mutated-non-small-cell-lung-cancer https://www.jnj.com/media-center/press-releases/new-tecvayli-data-demonstrates-superior-progression-free-and-overall-survival-as-early-as-first-relapse-in-multiple-myeloma • Building on the recent approval of TECVAYLI® plus DARZALEX FASPRO®, MajesTEC-9 is the second positive Phase 3 study to reinforce the strength of TECVAYLI® as early as second line • TECVAYLI®delivered deep and durable responses, with nearly two-thirds of patients achieving a complete response or better Fri, 29 May 2026 12:33:37 GMT https://www.jnj.com/media-center/press-releases/new-tecvayli-data-demonstrates-superior-progression-free-and-overall-survival-as-early-as-first-relapse-in-multiple-myeloma